320 related articles for article (PubMed ID: 15845217)
1. Clinical and histological features of multiple meningiomas compared with solitary meningiomas.
Huang H; Buhl R; Hugo HH; Mehdorn HM
Neurol Res; 2005 Apr; 27(3):324-32. PubMed ID: 15845217
[TBL] [Abstract][Full Text] [Related]
2. Correlation between histological grade, MIB-1, p53, and recurrence in 69 completely resected primary intracranial meningiomas with a 6 year mean follow-up.
Lanzafame S; Torrisi A; Barbagallo G; Emmanuele C; Alberio N; Albanese V
Pathol Res Pract; 2000; 196(7):483-8. PubMed ID: 10926326
[TBL] [Abstract][Full Text] [Related]
3. Proliferation and progesterone receptor status in benign meningiomas are not age dependent.
Roser F; Nakamura M; Ritz R; Bellinzona M; Dietz K; Samii M; Tatagiba MS
Cancer; 2005 Aug; 104(3):598-601. PubMed ID: 15952201
[TBL] [Abstract][Full Text] [Related]
4. The Ki-67 proliferation antigen in meningiomas. Experience in 600 cases.
Roser F; Samii M; Ostertag H; Bellinzona M
Acta Neurochir (Wien); 2004 Jan; 146(1):37-44; discussion 44. PubMed ID: 14740263
[TBL] [Abstract][Full Text] [Related]
5. Correlation between histological grade and MIB-1 and p53 immunoreactivity in meningiomas.
Ozen O; Demirhan B; Altinörs N
Clin Neuropathol; 2005; 24(5):219-24. PubMed ID: 16167545
[TBL] [Abstract][Full Text] [Related]
6. Recurrence of benign meningiomas: predictive value of proliferative index, BCL2, p53, hormonal receptors and HER2 expression.
Abdelzaher E; El-Gendi SM; Yehya A; Gowil AG
Br J Neurosurg; 2011 Dec; 25(6):707-13. PubMed ID: 20979437
[TBL] [Abstract][Full Text] [Related]
7. Progesterone-receptor index in meningiomas: correlation with clinico-pathological parameters and review of the literature.
Wolfsberger S; Doostkam S; Boecher-Schwarz HG; Roessler K; van Trotsenburg M; Hainfellner JA; Knosp E
Neurosurg Rev; 2004 Oct; 27(4):238-45. PubMed ID: 15168138
[TBL] [Abstract][Full Text] [Related]
8. Immunohistochemical expression of SPARC is correlated with recurrence, survival and malignant potential in meningiomas.
Bozkurt SU; Ayan E; Bolukbasi F; Elmaci I; Pamir N; Sav A
APMIS; 2009 Sep; 117(9):651-9. PubMed ID: 19703125
[TBL] [Abstract][Full Text] [Related]
9. MIB-1 labeling indices in benign, aggressive, and malignant meningiomas: a study of 90 tumors.
Abramovich CM; Prayson RA
Hum Pathol; 1998 Dec; 29(12):1420-7. PubMed ID: 9865827
[TBL] [Abstract][Full Text] [Related]
10. Histopathologic features and MIB-1 labeling indices in recurrent and nonrecurrent meningiomas.
Abramovich CM; Prayson RA
Arch Pathol Lab Med; 1999 Sep; 123(9):793-800. PubMed ID: 10458826
[TBL] [Abstract][Full Text] [Related]
11. Detection of progesterone receptor and the correlation with Ki-67 labeling index in meningiomas.
Mukherjee S; Ghosh SN; Chatterjee U; Chatterjee S
Neurol India; 2011; 59(6):817-22. PubMed ID: 22234191
[TBL] [Abstract][Full Text] [Related]
12. Gonadotropin-releasing hormone (GnRH) and its receptor in human meningiomas.
Hirota Y; Tachibana O; Uchiyama N; Hayashi Y; Nakada M; Kita D; Watanabe T; Higashi R; Hamada J; Hayashi Y
Clin Neurol Neurosurg; 2009 Feb; 111(2):127-33. PubMed ID: 18980792
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of 1p and 14q status, MIB-1 labeling index and progesterone receptor immunoexpression in meningiomas: Adjuncts to histopathological grading and predictors of aggressive behavior.
Kumar S; Kakkar A; Suri V; Kumar A; Bhagat U; Sharma MC; Singh M; Suri A; Sarkar C
Neurol India; 2014; 62(4):376-82. PubMed ID: 25237942
[TBL] [Abstract][Full Text] [Related]
14. Abundant immunohistochemical expression of dopamine D2 receptor and p53 protein in meningiomas: follow-up, relation to gender, age, tumor grade, and recurrence.
Trott G; Pereira-Lima JF; Leães CG; Ferreira NP; Barbosa-Coutinho LM; Oliveira MC
Braz J Med Biol Res; 2015 May; 48(5):415-9. PubMed ID: 25742638
[TBL] [Abstract][Full Text] [Related]
15. Prognostic significance of MIB-1, p53, and bcl-2 immunoreactivity in meningiomas.
Karamitopoulou E; Perentes E; Tolnay M; Probst A
Hum Pathol; 1998 Feb; 29(2):140-5. PubMed ID: 9490273
[TBL] [Abstract][Full Text] [Related]
16. An immunohistochemical study of HER2 expression in meningioma and its correlation with tumor grade.
Mahzouni P; Movahedipour M
Pathol Res Pract; 2012 Apr; 208(4):221-4. PubMed ID: 22420924
[TBL] [Abstract][Full Text] [Related]
17. Clinicopathologic features of aggressive meningioma emphasizing the role of radiotherapy in treatment.
Engenhart-Cabillic R; Farhoud A; Sure U; Heinze S; Henzel M; Mennel HD; Bertalanffy H
Strahlenther Onkol; 2006 Nov; 182(11):641-6. PubMed ID: 17072521
[TBL] [Abstract][Full Text] [Related]
18. Primary ear and temporal bone meningiomas: a clinicopathologic study of 36 cases with a review of the literature.
Thompson LD; Bouffard JP; Sandberg GD; Mena H
Mod Pathol; 2003 Mar; 16(3):236-45. PubMed ID: 12640104
[TBL] [Abstract][Full Text] [Related]
19. Oncocytic meningiomas: Cases with benign histopathological features and a favorable clinical course.
Gallina P; Buccoliero AM; Mariotti F; Mennonna P; Di Lorenzo N
J Neurosurg; 2006 Nov; 105(5):736-8. PubMed ID: 17121136
[TBL] [Abstract][Full Text] [Related]
20. Recurrences of meningiomas: predictive value of pathological features and hormonal and growth factors.
Maiuri F; De Caro MB; Esposito F; Cappabianca P; Strazzullo V; Pettinato G; de Divitiis E
J Neurooncol; 2007 Mar; 82(1):63-8. PubMed ID: 17225937
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
